BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+17.56%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$6.54B
AUM Growth
+$331M
(+5.3%)
Cap. Flow
-$370M
Cap. Flow
% of AUM
-5.66%
Top 10 Holdings %
Top 10 Hldgs %
39.82%
Holding
179
New
25
Increased
33
Reduced
89
Closed
18
Top Buys
| 1 |
Immunocore
IMCR
|
$65.3M |
| 2 |
Biohaven
BHVN
|
$46M |
| 3 |
Moderna
MRNA
|
$41.1M |
| 4 |
GE HealthCare
GEHC
|
$40.4M |
| 5 |
Boston Scientific
BSX
|
$30.3M |
Top Sells
| 1 |
Vertex Pharmaceuticals
VRTX
|
$108M |
| 2 |
UnitedHealth
UNH
|
$63.2M |
| 3 |
Evolent Health
EVH
|
$42.9M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$34.5M |
| 5 |
IQVIA
IQV
|
$34M |
Sector Composition
| 1 | Healthcare | 99.06% |
| 2 | Industrials | 0.83% |
| 3 | Energy | 0.03% |
| 4 | Consumer Discretionary | 0.02% |
| 5 | Communication Services | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Encompass Health
EHC
$12.5B
| $794K | 0.01% |
+11,900
| New | +$794K |
|
127
Protagonist Therapeutics
PTGX
$3.62B
| $688K | 0.01% |
30,000
| – | – |
|
128
Pfizer
PFE
$141B
| $658K | 0.01% |
22,868
+13,313
| +139% | +$383K |
|
129
Viridian Therapeutics
VRDN
$1.59B
| $653K | 0.01% |
30,000
-33,770
| -53% | -$736K |
|
130
Rocket Pharmaceuticals
RCKT
$358M
| $629K | 0.01% |
+21,000
| New | +$629K |
|
131
Merus
MRUS
$5.04B
| $624K | 0.01% |
22,700
-21,800
| -49% | -$600K |
|
132
Dynavax Technologies
DVAX
$1.19B
| $604K | 0.01% |
43,200
-40,000
| -48% | -$559K |
|
|
VERV
133
DELISTED
Verve Therapeutics
VERV
| $544K | 0.01% |
+39,000
| New | +$544K |
|
134
SPDR S&P Oil & Gas Exploration & Production ETF
XOP
$1.86B
| $534K | 0.01% |
3,900
| – | – |
|
135
Structure Therapeutics
GPCR
$1.14B
| $501K | 0.01% |
12,300
-4,500
| -27% | -$183K |
|
136
Supernus Pharmaceuticals
SUPN
$2.52B
| $437K | 0.01% |
15,100
-565,500
| -97% | -$16.4M |
|
137
DaVita
DVA
$9.72B
| $398K | 0.01% |
+3,800
| New | +$398K |
|
138
lululemon athletica
LULU
$23.8B
| $394K | 0.01% |
+770
| New | +$394K |
|
139
Life Time Group Holdings
LTH
$6.11B
| $380K | 0.01% |
+25,200
| New | +$380K |
|
140
Nike
NKE
$110B
| $369K | 0.01% |
+3,400
| New | +$369K |
|
141
Biomea Fusion
BMEA
$114M
| $363K | 0.01% |
+25,000
| New | +$363K |
|
|
BCYC
142
Bicycle Therapeutics
BCYC
$492M
| $362K | 0.01% |
20,000
-19,200
| -49% | -$347K |
|
143
Cardinal Health
CAH
$36B
| $353K | 0.01% |
+3,500
| New | +$353K |
|
144
C4 Therapeutics
CCCC
$182M
| $350K | 0.01% |
+62,000
| New | +$350K |
|
|
WW
145
DELISTED
WW International
WW
| $350K | 0.01% |
+40,000
| New | +$350K |
|
146
Viking Therapeutics
VKTX
$3.02B
| $326K | 0.01% |
+17,500
| New | +$326K |
|
|
AUTL
147
Autolus Therapeutics
AUTL
$383M
| $322K | ﹤0.01% |
+50,000
| New | +$322K |
|
148
89bio
ETNB
$1.37B
| $226K | ﹤0.01% |
20,200
-19,000
| -48% | -$212K |
|
149
Viatris
VTRS
$12.3B
| $195K | ﹤0.01% |
18,003
-158,845
| -90% | -$1.72M |
|
150
VanEck Junior Gold Miners ETF
GDXJ
$6.91B
| $190K | ﹤0.01% |
5,000
| – | – |
|